A New Era in Alzheimer’s Detection
Circular Genomics, a leader in circular RNA-based precision medicine, has closed a $15 million Series A financing round. This funding will accelerate the development of its innovative platform for the early detection of Alzheimer’s disease.
The financing was led by Mountain Group Partners. Other participants included Poplar Grove Investors, HIP Fund, and the Alzheimer’s Drug Discovery Foundation (ADDF).
Addressing a Critical Need
Alzheimer’s disease affects over seven million Americans. Diagnosis is often delayed by two to three years after symptoms appear. This delay limits treatment options and impacts quality of life.
Traditional diagnostic methods like PET scans and spinal fluid tests are expensive and invasive. A more accessible and accurate solution is urgently needed.
Key Statistics on Alzheimer’s Disease
| Statistic | Value |
|---|---|
| Americans Affected | >7 Million |
| Diagnosis Delay | 2-3 Years |
| Undiagnosed Dementia Cases | ~75% |
| Dementia Cases with No Formal Diagnosis | ~50% |
The Power of Circular RNA
Circular Genomics’ platform uses circular RNA (circRNA), a new class of biomarkers found in the blood. These molecules provide a real-time window into brain health. They can detect Alzheimer’s-related changes before symptoms become apparent.
This technology offers a non-invasive and cost-effective way to identify individuals at risk. It also helps in monitoring disease progression and treatment response.
A Strategic Investment
The new funding will be used to:
- Expand clinical validation studies
- Enhance the circRNA platform
- Form strategic partnerships
- Grow the scientific and commercial teams
“This Series A financing represents a pivotal milestone in our journey to transform precision neurology,” said Paul Sargeant, CEO of Circular Genomics. “The strong support from our world-class investors validates the breakthrough potential of our circular RNA platform.”
The Future of Alzheimer’s Care
The development of new therapies for Alzheimer’s has created a need for better diagnostic tools. Circular Genomics’ technology is poised to meet this demand. It has the potential to shift Alzheimer’s diagnosis from a late-stage, reactive process to an early, proactive one.
This innovation could change how we approach Alzheimer’s care. It offers hope for earlier intervention and better outcomes for individuals and families affected by the disease.
For more info visit: https://www.circulargenomics.com/
References
[1] Circular Genomics. “Circular Genomics Announces Closure of $15 Million Series A Financing to Advance First-in-Class Circular RNA Platform for Early Detection of Alzheimer’s Disease.” PR Newswire, 1 Dec. 2025, https://www.prnewswire.com/news-releases/circular-genomics-announces-closure-of-15-million-series-a-financing-to-advance-first-in-class-circular-rna-platform-for-early-detection-of-alzheimers-disease-302628504.html.
